Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 17, 2005

View Archived Issues

Amyloidosis and renal disease progression

Q3 progress at Incyte

CombiMatrix and Novavax collaborate on technology for vaccine production

Financing at AM-Pharma to advance programs into phase II

Boehringer Ingelheim and Biolipox partner on drugs for pain and inflammation

Tolvaptan for autosomal dominant polycystic kidney disease

Endogenous stem cell activation for the treatment of Parkinson's

Treating glucose-deprived neurons ameliorates cognitive deficits and oxidative damage

Levosimendan reported effective in the treatment of ADHF

Synairgen begins phase I trial of IFN-beta to reduce asthma exacerbations

tgAAC-09 begins phase II study in South Africa

New approaches to pandemic influenza vaccine development

Phase I/II trial evaluates MGCD-0103 and azacitidine for MDS and AML

Welichem begins new initiatives with Chinese partners

Spectrum reports product development highlights of third quarter

New selective inhibitor of enterovirus replication for myocarditis

Antitumor effects of antibody-drug conjugate targeting glycoprotein NMB

NLNQ-1: a novel hypoxia-selective cytotoxin and radiosensitizer

EP4 agonism as a treatment for diabetic nephropathy

Ghrelin reverses endothelial function in patients with metabolic syndrome

New p38 MAPK inhibitor shows joint-protective effects in rat adjuvant-induced arthritis

Altana withdraws Daxas MAA

Novel FXR activator shows promise in the treatment of hepatic fibrosis

Recent patents describe novel anti-hepatitis agents

New CETP inhibitors disclosed in recent Merck & Co. patent

New treatments for neuropsychiatric disorders claimed in recent patent literature

Update on SCH-503034 in the treatment of hepatitis C

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...